<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">WJCD</journal-id><journal-title-group><journal-title>World Journal of Cardiovascular Diseases</journal-title></journal-title-group><issn pub-type="epub">2164-5329</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/wjcd.2023.133008</article-id><article-id pub-id-type="publisher-id">WJCD-123756</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Epidemiology and Management of Heart Failure in the Medicine Department of Tombouctou Hospital
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Bassirima</surname><given-names>Traoré</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Souleymane</surname><given-names>Mariko</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Samba</surname><given-names>Sidibé</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Karamoko</surname><given-names>Kantako</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mariam</surname><given-names>Sako</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Massama</surname><given-names>Konaté</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Nouhoum</surname><given-names>Diallo</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Abdoul</surname><given-names>Karim Sacko</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kalifa</surname><given-names>Diallo</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Youssouf</surname><given-names>Kassambara</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Djibril</surname><given-names>Kassogue</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Oumar</surname><given-names>Ongoiba</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Oumar</surname><given-names>Sanogo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ichaka</surname><given-names>Menta</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Souleymane</surname><given-names>Coulibaly</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>Department of Cardiology, Point G University Hospital, Bamako, Mali</addr-line></aff><aff id="aff1"><addr-line>Department of Medicine, Tombouctou Hospital, Tombouctou, Mali</addr-line></aff><aff id="aff3"><addr-line>Department of Cardiology, Mali Hospital, Bamako, Mali</addr-line></aff><aff id="aff4"><addr-line>Department of Cardiology, CHU Gabriel TOURE, Bamako, Mali</addr-line></aff><pub-date pub-type="epub"><day>17</day><month>03</month><year>2023</year></pub-date><volume>13</volume><issue>03</issue><fpage>105</fpage><lpage>113</lpage><history><date date-type="received"><day>12,</day>	<month>January</month>	<year>2023</year></date><date date-type="rev-recd"><day>17,</day>	<month>March</month>	<year>2023</year>	</date><date date-type="accepted"><day>20,</day>	<month>March</month>	<year>2023</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Introduction:
   Heart failure is a complex syndrome and very frequently observed and secondary to the outcome of many advanced heart diseases. It is made up of a set of symptoms that reflect the tissue and visceral consequences of heart failure. <b>The</b> <b>objective</b> was to determine the hospital prevalence and to describe the management of heart failure in the medical department of Tombouctou hospital in Mali. <b>Methods:</b> This is a descriptive cross-sectional study with retrospective data collection, carried out over 24 months and involving the analysis of 266 records of patients hospitalized for heart failure. <b>Results:</b> The frequency of heart failure was 17.6% with a female predominance. The average age was 48 years with extremes of 16 and 90 years. Cardiovascular risk factors were dominated by high blood pressure with 38%. Global heart failure was the mode of discovery in 72.2% of cases. The etiologies were dominated by hypertensive dilated cardiomyopathy in 36.8% and peripartum cardiomyopathy in 32% of cases. The majority of our patients benefited from diuretic treatment, i.e. 95.9% frequency; with a favorable evolution in 96.2% of cases. We recorded 10 deaths, i.e. a lethality of 3.7%. We report some difficulties encountered during our security study because Tombouctou is a war zone and the lack of a technical platform for biology such as (BNP or NT-proBNP). <b>Conclusion:</b> Heart failure is a real public health problem. Its prevalence is increasing due to the aging of the population and especially the poor management of arterial hypertension in our context.
 
</p></abstract><kwd-group><kwd>Heart Failure</kwd><kwd> Epidemiology</kwd><kwd> Etiology</kwd><kwd> Treatment</kwd><kwd> Tombouctou Hospital</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Heart failure (HF) is a frequent and serious pathology. The European Society of Cardiology (ESC) in its 2021 recommendations, classifies heart failure into three phenotypes: heart failure with reduced ejection fraction (LVEF ≤ 40%), heart failure with slightly reduced ejection fraction (LVEF included between 41% and 49%) and heart failure with preserved ejection fraction (LVEF ≥ 50%) [<xref ref-type="bibr" rid="scirp.123756-ref1">1</xref>] . Worldwide, it affects approximately 15 million people, including approximately 5 million in the United States of America [<xref ref-type="bibr" rid="scirp.123756-ref2">2</xref>] . In Europe, it affects 1% to 2% of people between 50 and 59 years old and around 5% to 10% of people aged between 80 and 89 years old [<xref ref-type="bibr" rid="scirp.123756-ref3">3</xref>] . The incidence of this syndrome is only increasing and the number of heart failure patients is expected to double by 2040 [<xref ref-type="bibr" rid="scirp.123756-ref4">4</xref>] . As for Africa, it varies from one country to another, so it is 15% in Morocco [<xref ref-type="bibr" rid="scirp.123756-ref5">5</xref>] , 37.7% in Senegal, 41.3% [<xref ref-type="bibr" rid="scirp.123756-ref6">6</xref>] in Mali [<xref ref-type="bibr" rid="scirp.123756-ref7">7</xref>] . Its epidemiology is little known in our country despite its considerable economic impact on the health system. Its prevalence continues to increase in our developing countries due, in particular, to arterial hypertension and coronary disease. In Tombouctou, no study was done on heart failure, hence the interest of our study. The objectives of this study were to determine the hospital prevalence and to describe the management of heart failure in the medical department of Tombouctou hospital in Mali.</p></sec><sec id="s2"><title>2. Material and Method</title><p>This was a cross-sectional, descriptive study with a retrospective collection of data from January 2020 to December 2021 at the level of the medicine department of Tombouctou hospital, during which we included 266 patients with heart failure. The volunteers were patients hospitalized for heart failure. After obtaining informed consent, they were included in the study.</p><sec id="s2_1"><title>2.1. Collection of Data</title><p>Data collection was done from hospital records.</p><p>The data collected were socio-demographic, clinical (functional signs, physical signs), cardiovascular and para-clinical risk factors (trans-thoracic echocardiography, electrocardiogram and radiology).</p></sec><sec id="s2_2"><title>2.2. Judging Criteria</title><p>Clinical: patients aged 16 and over who have presented symptoms suggestive of heart failure and who have been hospitalized in the department.</p><p>The positive diagnosis of heart failure was based on:</p><p>&#173; A clinical syndrome of heart failure;</p><p>&#173; An increase in left ventricular filling pressures with or without left ventricular dysfunction.</p></sec><sec id="s2_3"><title>2.3. Operational Definitions</title><p>Heart failure (HF) is therefore defined by the inability of the heart muscle to provide normal systemic blood flow with a normal filling pressure regime.</p><p>Signs of heart failure (HF) were dyspnea (according to NYHA), crackles, left canter sound for left IC and hepatalgia, right canter sound, hepatomegaly, edema of the lower limbs, turgidity of the jugular veins for the right IC.</p></sec><sec id="s2_4"><title>2.4. Variables</title><p>Data were collected using the medical observation record and recorded in a questionnaire. This questionnaire was written by the scientific manager and the principal investigator and included:</p><p>The statistical population studied was patients with clinical and echocardiographic heart failure.</p><p>The variables studied were:</p><p>&#173; Quantitative included the age of patients, the seniority of hypertension and diabetes, the number of days of hospitalization and death.</p><p>&#173; Qualitative included sex of patients, symptoms, description of echocardiographic doppler, electrocardiographic and biology abnormalities.</p><p>The questionnaire was subjected to a follow-up test on the recruitment procedure and data analysis.</p><p>Excel 2016 software was used for data entry and then analyzed by SPSS 24 software. The demographic, clinical and paraclinical characteristics of the patients were described. The qualitative data were presented by their proportion, expressed as a percentage, and the quantitative data by their median or their mean (plus or minus standard deviation).</p></sec><sec id="s2_5"><title>2.5. Ethics</title><p>Informed consent was obtained with strict confidentiality.</p></sec></sec><sec id="s3"><title>3. Results</title><p>The general characteristics of the population studied:</p><p>Out of 1513 hospitalized patients, 266 had heart failure. The hospital prevalence was 17.6%. The average age was 48 years with extremes of 16 and 90 years (<xref ref-type="table" rid="table1">Table 1</xref>) the majority of our patients lived in the city of Tombouctou and surrounding (78.9%) with a low income level (80.4%). Chronic heart failure was the most common medical history (15.4%). Cardiovascular risk factors were dominated by arterial hypertension with 38% and tobacco with 13% (<xref ref-type="table" rid="table2">Table 2</xref>). The mode of discovery was the table of global heart failure (72.2%). The clinical symptomatology was dominated by dyspnea (89%), cough (73.6%) and edema of the lower limbs (46.6%). On chest X-ray, cardiomegaly was present in 17.7% of cases with vascular redistribution at the top in 12.7% of cases. On biology, anemia (22.2%), moderate to severe renal insufficiency 29.7% and hypokalemia 12.8% were noted. Regular sinus tachycardia was the dominant abnormality on the electrocardiogram (46.6%) followed by left ventricular hypertrophy (33.8%), ischemia (22.2%) and complete arrhythmia by fibrillation atrial (16.5%). Transthoracic Doppler echocardiography found dilatation of the left ventricle in 70.3% of cases, with an average end-diastolic diameter of 60 mm associated with a drop in the systolic fraction of the left ventricle in 77.8% of cases, with a fraction of mean ejection in 39.9% and kinetic abnormalities in 16.2% of cases (<xref ref-type="table" rid="table3">Table 3</xref>).</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Distribution of patients according to age and sex</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="3"  >Age</th><th align="center" valign="middle"  colspan="4"  >Sex</th></tr></thead><tr><td align="center" valign="middle"  colspan="2"  >Male</td><td align="center" valign="middle"  colspan="2"  >Female</td></tr><tr><td align="center" valign="middle" >Effectives</td><td align="center" valign="middle" >%</td><td align="center" valign="middle" >Effectives</td><td align="center" valign="middle" >%</td></tr><tr><td align="center" valign="middle" >16 - 45 years</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >7.5</td><td align="center" valign="middle" >101</td><td align="center" valign="middle" >37.9</td></tr><tr><td align="center" valign="middle" >46 - 60 years</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >10.9</td></tr><tr><td align="center" valign="middle" >Age &gt; 60 years</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >22.5</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >9</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >112</td><td align="center" valign="middle" >42.1</td><td align="center" valign="middle" >154</td><td align="center" valign="middle" >57.9</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Distribution of patients according to cardiovascular risk factors</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Risk factors</th><th align="center" valign="middle" >Effectives</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >Arterial hypertension</td><td align="center" valign="middle" >101</td><td align="center" valign="middle" >38%</td></tr><tr><td align="center" valign="middle" >Age ≥ 60</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >19%</td></tr><tr><td align="center" valign="middle" >Tobacco</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >13%</td></tr><tr><td align="center" valign="middle" >Sedentary lifestyle</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >8.6%</td></tr><tr><td align="center" valign="middle" >Diabetes</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >6%</td></tr><tr><td align="center" valign="middle" >Obesity</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.7%</td></tr></tbody></table></table-wrap><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Distribution of patients according to the results of cardiac Doppler ultrasound</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >FEVG</th><th align="center" valign="middle"  colspan="2"  >Effectives</th><th align="center" valign="middle"  colspan="2"  >Percentage</th></tr></thead><tr><td align="center" valign="middle" >Reduced</td><td align="center" valign="middle"  colspan="2"  >145</td><td align="center" valign="middle"  colspan="2"  >54.5%</td></tr><tr><td align="center" valign="middle" >Moderately reduced</td><td align="center" valign="middle"  colspan="2"  >62</td><td align="center" valign="middle"  colspan="2"  >23.3%</td></tr><tr><td align="center" valign="middle" >Preserved</td><td align="center" valign="middle"  colspan="2"  >59</td><td align="center" valign="middle"  colspan="2"  >22.2%</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle"  colspan="2"  >266</td><td align="center" valign="middle"  colspan="2"  >100</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Total</td><td align="center" valign="middle"  colspan="2"  >266</td><td align="center" valign="middle" >100</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><sec id="s3_1"><title>3.1. Etiological Factors of Heart Failure</title><p>Etiologies of heart failure were dominated by hypertensive dilated cardiomyopathy (36.8%), peripartum cardiomyopathy 32%, ischemic heart disease (16.2%), restrictive heart disease (5.6%), hypertrophic heart disease (4.5%) and Chronic heart pulmonale (2.6%) (<xref ref-type="table" rid="table4">Table 4</xref>).</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Distribution of patients according to etiology of heart failure</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Etiology</th><th align="center" valign="middle" >Effectives</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >Dilated cardiomyopathy</td><td align="center" valign="middle" >98</td><td align="center" valign="middle" >36.8%</td></tr><tr><td align="center" valign="middle" >Peripartum cardiomyopathy</td><td align="center" valign="middle" >85</td><td align="center" valign="middle" >32%</td></tr><tr><td align="center" valign="middle" >Ischemic heart disease</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >16.2%</td></tr><tr><td align="center" valign="middle" >Restrictive heart disease</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >5.6%</td></tr><tr><td align="center" valign="middle" >Hypertrophic heart disease</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >4.5%</td></tr><tr><td align="center" valign="middle" >Chronic heart pulmonale</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >2.6%</td></tr><tr><td align="center" valign="middle" >Mitral stenosis</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.1%</td></tr><tr><td align="center" valign="middle" >Others</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.1%</td></tr></tbody></table></table-wrap></sec><sec id="s3_2"><title>3.2. The Treatment</title><p>On admission, our patients received medical treatment as follows: diuretics (95.9%), beta-blockers (93.6%), ACE inhibitors (87.2%), heparins (69.2%), vitamin K antagonists (AVK) (22.6%), iron (12%), antirhythmics (8.3%), angiotensin II receptor antagonists (ARA II) (4.1), nitrate derivatives (1.1%), unfortunatelynone of our patients benefited from coronary angiography or resynchronization due to lack of technical facilities. The discharge treatment consisted of: loop diuretics (92.1%), beta-blockers (90.9%), ACE inhibitors (87.2%), anti-aldosterone (41.7%) and AVK (22.6 %).</p></sec><sec id="s3_3"><title>3.3. Hospital Evolution</title><p>The average hospital stay was 5.7 days. The evolution was favorable in the majority of cases (96.2%). Complications included 15.4% complete arrhythmia due to atrial fibrillation, 7.1% intracavitary thrombus and 1.5% stroke and two cases of refractor heart failure. The rate of recurrence of hospitalization for decompensation was 12.8%.</p><p>We recorded 10 deaths, i.e. a lethality of 3.7% (<xref ref-type="table" rid="table5">Table 5</xref>).</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Distribution of patients according to evolution under treatment and length of hospital stay</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Duration of hospitalization</th><th align="center" valign="middle"  colspan="3"  >Evolution under treatment</th><th align="center" valign="middle"  rowspan="2"  >Total</th></tr></thead><tr><td align="center" valign="middle" >Favorable without complication</td><td align="center" valign="middle" >Favorable with complication</td><td align="center" valign="middle" >Death</td></tr><tr><td align="center" valign="middle" >1 - 7 days</td><td align="center" valign="middle" >163 (61.3%)</td><td align="center" valign="middle" >38 (14.3%)</td><td align="center" valign="middle" >8 (3%)</td><td align="center" valign="middle" >209 (78.6)</td></tr><tr><td align="center" valign="middle" >8 days - 1 month</td><td align="center" valign="middle" >28 (10.5%)</td><td align="center" valign="middle" >27 (10.1%)</td><td align="center" valign="middle" >2 (0.7%)</td><td align="center" valign="middle" >57 (21.4%)</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >191 (71.8%)</td><td align="center" valign="middle" >65 (24.4%)</td><td align="center" valign="middle" >10 (3.7%)</td><td align="center" valign="middle" >266 (100%)</td></tr></tbody></table></table-wrap></sec></sec><sec id="s4"><title>4. Discussion</title><p>Heart failure is an increasingly common condition in our context.</p><p>The prevalence of heart failure in our series is about 17.6% higher than that found in Morocco 15% [<xref ref-type="bibr" rid="scirp.123756-ref5">5</xref>] ; but remains lower than those reported in other sub-Saharan African countries, in particular 25.6% from Togo [<xref ref-type="bibr" rid="scirp.123756-ref8">8</xref>] , 37.7% from Dakar [<xref ref-type="bibr" rid="scirp.123756-ref6">6</xref>] , 41.3% from Bamako [<xref ref-type="bibr" rid="scirp.123756-ref7">7</xref>] , 45.9% of Congo Brazzaville [<xref ref-type="bibr" rid="scirp.123756-ref9">9</xref>] this difference can be explained by the financial and security difficulties preventing patients not residing in the city of Tombouctou from consulting.</p><p>The average age was 48 years, relatively young, lower than many studies carried out in Africa on heart failure (52.5) by Pio [<xref ref-type="bibr" rid="scirp.123756-ref8">8</xref>] , (59) by Nana [<xref ref-type="bibr" rid="scirp.123756-ref10">10</xref>] , (56.2) from Doulgou [<xref ref-type="bibr" rid="scirp.123756-ref11">11</xref>] . This average age is also lower than that found in France (79 years) by the RS2002-2 survey [<xref ref-type="bibr" rid="scirp.123756-ref12">12</xref>] and in the United States (72.4 years) by ADHERE [<xref ref-type="bibr" rid="scirp.123756-ref13">13</xref>] . The young age of the Malian population and the high frequency of peripartum heart disease could explain the young average age of our study unlike in Europe and the United States where the population is aging [<xref ref-type="bibr" rid="scirp.123756-ref4">4</xref>] .</p><p>The female gender was noted in 57.9% of cases. This proportion was also found by Maiga AK [<xref ref-type="bibr" rid="scirp.123756-ref14">14</xref>] , Traor&#233; [<xref ref-type="bibr" rid="scirp.123756-ref15">15</xref>] in Mali and ADHERE in the United States [<xref ref-type="bibr" rid="scirp.123756-ref13">13</xref>] , unlike Djamal and Karima who noted a predominance of the male sex [<xref ref-type="bibr" rid="scirp.123756-ref16">16</xref>] [<xref ref-type="bibr" rid="scirp.123756-ref17">17</xref>] . Arterial hypertension was the most described risk factor 38% in line with most African but also African-American studies on heart failure [<xref ref-type="bibr" rid="scirp.123756-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.123756-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.123756-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.123756-ref19">19</xref>] . The most found mode of discovery was the table of congestive heart failure, i.e. 72.2% frequency in accordance with the rest of the literature [<xref ref-type="bibr" rid="scirp.123756-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.123756-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.123756-ref20">20</xref>] explaining the severity of the disease and due in part to the delay of support.</p><p>The origin of heart failure is mainly hypertensive in our series and that of Ikama [<xref ref-type="bibr" rid="scirp.123756-ref9">9</xref>] , it constitutes a real public health problem. Unlike European, American and Thai studies, it is of ischemic origin [<xref ref-type="bibr" rid="scirp.123756-ref13">13</xref>] . This difference could be explained by the more efficient diagnostic means, but perhaps also by the change in lifestyle and urbanization.</p><p>Our patients did not benefit from biology such as BNP or NT-proBNP due to the lack of a technical platform. 29.7% of our patients had moderate to severe renal insufficiency, 22.2% had anemia, and 12.8% had hypokalaemia, in agreement with Jamal [<xref ref-type="bibr" rid="scirp.123756-ref16">16</xref>] .</p><p>On chest radiography, cardiomegaly was present in 17.7% of cases, with signs of pulmonary overload in 12.7% of cases; lower than the 94.6% of Ou&#233;draogo [<xref ref-type="bibr" rid="scirp.123756-ref21">21</xref>] and 86% of Jamal [<xref ref-type="bibr" rid="scirp.123756-ref16">16</xref>] due to the fact that all of our patients did not benefit from chest X-ray.</p><p>Left ventricular hypertrophy (33%) was the dominant anomaly on the electrocardiogram followed by complete arrhythmia by atrial fibrillation (16.5%) comparable to that of Ou&#233;draogo [<xref ref-type="bibr" rid="scirp.123756-ref21">21</xref>] and Kambir&#233; [<xref ref-type="bibr" rid="scirp.123756-ref22">22</xref>] in Burkina. It was higher than those of the SAFETY [<xref ref-type="bibr" rid="scirp.123756-ref23">23</xref>] and Jamal [<xref ref-type="bibr" rid="scirp.123756-ref16">16</xref>] studies. This ventricular hypertrophy is an adaptation mechanism of the heart at the onset of heart failure.</p><p>Cardiac Doppler ultrasound was performed in all our patients, because it is a key examination in the management of heart failure, whether at the time of diagnosis of the disease or during follow-up. The mean LVEF in our study was 39.9% similar to those reported by Tougouma (32%) [<xref ref-type="bibr" rid="scirp.123756-ref24">24</xref>] , Jamal (36%) [<xref ref-type="bibr" rid="scirp.123756-ref16">16</xref>] and Maggioni (38%) [<xref ref-type="bibr" rid="scirp.123756-ref25">25</xref>] . Severely impaired LVEF and the presence of other abnormalities testify to the advanced stage of heart failure in our context.</p><p>The clinical benefit of diuretic administration in AHF is universally accepted, loop diuretics are the first choice in AHF [<xref ref-type="bibr" rid="scirp.123756-ref23">23</xref>] [<xref ref-type="bibr" rid="scirp.123756-ref24">24</xref>] . The frequency of use of diuretics in our study is consistent with that reported in the literature where diuretics were the first molecules prescribed in AHF (89.7% to 90%) in the literature [<xref ref-type="bibr" rid="scirp.123756-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.123756-ref26">26</xref>] [<xref ref-type="bibr" rid="scirp.123756-ref27">27</xref>] . This is due to the clinical stage of the disease with water and sodium retention.</p><p>We recorded a low case fatality rate of 3.7% compared to most of the literature due to the small sample size [<xref ref-type="bibr" rid="scirp.123756-ref27">27</xref>] .</p><p>The rate of recurrence of hospitalization recorded in this series was 12.8% lower than that of the literature of 22% to 30% [<xref ref-type="bibr" rid="scirp.123756-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.123756-ref20">20</xref>] [<xref ref-type="bibr" rid="scirp.123756-ref28">28</xref>] [<xref ref-type="bibr" rid="scirp.123756-ref29">29</xref>] .</p></sec><sec id="s5"><title>5. The Limits of Our Study</title><p>The small size of our sample and the results obtained could therefore not be extrapolated to the general population; Non-production of BNP or NT-proBNP due to the lack of a technical platform; financial difficulties and the security situation linked to the rebellion in the area prevented patients from being consulted at the hospital.</p></sec><sec id="s6"><title>6. Conclusion</title><p>Heart failure is a real public health problem. Its prevalence is increasing due to the aging of the population and especially the poor management of arterial hypertension in our country. The etiology of heart failure in our series is dominated by hypertensive heart disease and peripartum cardiomyopathy. Early diagnosis and management of hypertension will reduce the prevalence of heart failure.</p></sec><sec id="s7"><title>7. Recommendations</title><p>We focus on sensitizing the population and health workers on the regular and correct monitoring of arterial hypertension; prenatal consultation.</p><p>At the level of political decision-makers: Reinforce accessibility to care.</p><p>Research: We believe further research is needed nationally and in order to identify the characteristics of this disease.</p></sec><sec id="s8"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></sec><sec id="s9"><title>Cite this paper</title><p>Traor&#233;, B., Mariko, S., Sidib&#233;, S., Kantako, K., Sako, M., Konat&#233;, M., Diallo, N., Sacko, A.K., Diallo, K., Kassambara, Y., Kassogue, D., Ongoiba, O., Sa- nogo, O., Menta, I. and Coulibaly, S. (2023) Epidemiology and Management of Heart Failure in the Medicine Department of Tom- bouctou Hospital. World Journal of Cardiovascular Diseases, 13, 105-113. https://doi.org/10.4236/wjcd.2023.133008</p></sec></body><back><ref-list><title>References</title><ref id="scirp.123756-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) (2021) 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Heart Journal, 42, 3599-3726.</mixed-citation></ref><ref id="scirp.123756-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Knaus, W.A., et al. (1985) APACHE II: A Severity of Disease Classification System. Critical Care Medicine, 13, 818-829.  
https://doi.org/10.1097/00003246-198510000-00009</mixed-citation></ref><ref id="scirp.123756-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Hunt, S.A., et al. (2001) ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary. Journal of the American College of Cardiology, 38, 2101-2113.</mixed-citation></ref><ref id="scirp.123756-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Rich, M. (1997) CONGESTIVE HEART FAILURE IN OLDER ADULTS: Epidemiology, Pathophysiology and Etiology of Congestive Heart Failure in Older Adults. Journal of the American Geriatrics Society, 45, 968-974.  
https://doi.org/10.1111/j.1532-5415.1997.tb02968.x</mixed-citation></ref><ref id="scirp.123756-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Benyass, A., Bouzelmat, H., Jaakik, I., Asfalou, I., Bouzerda, A., Chaib, A., Sabry, M., Raissouni, M., Kendoussi, M., Moustaghfir, A., Zbir, E., Had, A., Boukili, M.A. and Hamani, A. (2011) Heart Failure (IC) in a Moroccan Hospital Center: Epidemiological, Clinical and Evolutionary Aspects. Med Maghreb, 187, 35-41.</mixed-citation></ref><ref id="scirp.123756-ref6"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Thiam</surname><given-names> M. </given-names></name>,<etal>et al</etal>. (<year>2003</year>)<article-title>Heart Failure in African Cardiology Settings</article-title><source> Bulletin de la Societe de Pathologie Exotique</source><volume> 96</volume>,<fpage> 217</fpage>-<lpage>218</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.123756-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Diallo, B., Sanogo, K., Diakite, S., Diarra, M.B. and Toure, M.K. (2004) Heart Failure at the Point G Hospital. Mali Medical, 9, 15-17.</mixed-citation></ref><ref id="scirp.123756-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Pio, M., Afassinou, Y., Pessinaba, S., et al. (2014) Epidémiologie et étiologies des insuffisances cardiaques à Lomé. The Pan African Medical Journal, 18, Article 183.</mixed-citation></ref><ref id="scirp.123756-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Ikama, M.S., Kimbally-Kaky, G., Gombet, T., Ellenga-Mbolla, B.F., Dilou-Bassemouka, L., et al. (2008) Heart Failure in the Elderly in Brazzaville: Clinical, Etiological and Evolutionary Aspects. Medecine Tropicale, 68, 257-260.</mixed-citation></ref><ref id="scirp.123756-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Nana, K.L., Dzudie, T.A., Djomou, N.F.A., et al. (2018) Comparative Study between Heart Failure with Preserved and Altered Ejection Fraction in the City of Douala. 11th Congress of the Cameroonian Society of Cardiology. Tropical Cardiology, 151, Article 27.</mixed-citation></ref><ref id="scirp.123756-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Doulgou, S. (n.d.) Decompensation Factors for Heart Failure in the CHUYO Cardiology Department. Medical Thesis, University of Ouagadougou, No. 3566, 154 p.</mixed-citation></ref><ref id="scirp.123756-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Saudubray, T., Saudubray, C., Viboud, C., Jondeau, G., Valleron, A.-J., Flahault, A. and Hanslik, T. (2005) Prevalence and Management of Heart Failure in France: National Survey of General Practitioners in the Sentinels Network. Journal of Internal Medicine, 26, 845-850. https://doi.org/10.1016/j.revmed.2005.04.038</mixed-citation></ref><ref id="scirp.123756-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Adams, K.F., Fonarow, G.C., Emerman, C.L., LeJemtel, T.H., Costanzo, M.R., Abraham, W.T., et al. (2005) Characteristics and Outcomes of Patients Hospitalized for Heart Failure in the United States: Rationale, Design, and Preliminary Observations from the First 100,000 Cases in the Acute Decompensated Heart Failure National Registry (ADHERE). American Heart Journal, 149, 209-216.  
https://doi.org/10.1016/j.ahj.2004.08.005</mixed-citation></ref><ref id="scirp.123756-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Maiga, A.K., Doumbia, C.T. and Fofana, D. (2019) Beta Blockers in the Treatment of Heart Failure in the Cardiology Department of the CHU Mother-Child (CHU-ME) “Le Luxembourg”. Health Science and Disease, 20, 30 p.</mixed-citation></ref><ref id="scirp.123756-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Traore, S. (2011) Epidemiological, Etiological, Clinical and Therapeutic Study of Heart Failure in Rural Areas. Ph.D. Thesis, University of Bamako, Bamako, Mali, 43-47, 12.</mixed-citation></ref><ref id="scirp.123756-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Kheyi, J., Benelmakki, A., Bouzelmat, H. and Chaib, A. (2016) Epidemiology and Management of Heart Failure in a Moroccan Center. The Pan African Medical Journal, 24, Article 85.</mixed-citation></ref><ref id="scirp.123756-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Karima, C., Nabila, H. and Mebarek, B. (2015) Epidemiological Study of Heart Failure. Ph.D. Thesis, University of Abou Bekr Belkaid, Tlemcen, Algeria, 42-46.</mixed-citation></ref><ref id="scirp.123756-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Bivigou, E.A., Allognon, M.C., Ndoume, F., Mipinda, J.B. and Nzengue, E.E. (2018) Lethality of Heart Failure at the Center Hospitalier Universitaire de Libreville (CHUL) and Associated Factors. Pan African Medical Journal, 31, Article 27.  
https://doi.org/10.11604/pamj.2018.31.27.13259</mixed-citation></ref><ref id="scirp.123756-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Makubi, A., Hage, C., Lwakatare, J., et al. (2014) Contemporary Aetiology, Clinical Characteristics and Prognosis of Adults with Heart Failure Observed in a Tertiary Hospital in Tanzania: The Prospective Tanzania Heart Failure (TaHeF) Study. Heart, 100, 1235-1241. https://doi.org/10.1136/heartjnl-2014-305599</mixed-citation></ref><ref id="scirp.123756-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Jouini, S., Manai, H., Slimani, O., Hedhli, H., Hebaieb, F., Mezghanni, M., Aloui, A. and Kaddour, R.B. (2019) Epidemiological Profile and Prognosis of Acute Heart Failure: Experience of the Emergency Department of Charles Nicole Hospital in Tunis from 2013 to 2014. Pan African Medical Journal, 33, Article 251.  
https://doi.org/10.11604/pamj.2019.33.251.17207</mixed-citation></ref><ref id="scirp.123756-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Ouédraogo, E.W.M., Ouédraogo, S., Bamouni, J., Banda, A., Kientega, H., Ouédraogo, T., Somé, J.W., Yaméogo, N.V. and Zabsonré, P. (2022) Cardiac Failure with Altered Ejection Fraction in African Rural Environment: Clinical and Paraclinical Characteristics in Ouahigouya (Burkina Faso). Health Science and Disease, 23, 46-50.</mixed-citation></ref><ref id="scirp.123756-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Kambiré, Y., Konaté, L., Diallo, I., Millogo, G.R.C., Kologo, K.J., Tougouma, J.B., Samadoulougou, A.K. and Zabsonré, P. (2019) Evaluation of the Medical Management of Heart Failure at National Hospital Blaise COMPAORE. Annals of Cardiology and Angiology, 68, 22-27. https://doi.org/10.1016/j.ancard.2018.04.006</mixed-citation></ref><ref id="scirp.123756-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Chable, H. (2013) Descriptive Study of the Epidemiological, Clinical and Therapeutic Aspects of Elderly People with Heart Failure Hospitalized in the Geriatric Post- Emergency. Safety Study. Medical Thesis, University of Limoges, Limoges.</mixed-citation></ref><ref id="scirp.123756-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Tougouma, J.B., Yaméogo, A.A., Hema, A., et al. (2015) Heart Failure with Impaired Systolic Function: Sociodemographic, Etiological and Evolutionary Aspects at the CHUSS of Bobo-Dioulasso (Burkina Faso). Journal of the Clinical Biology Society of Benin, 23, 77-82.</mixed-citation></ref><ref id="scirp.123756-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Maggioni, A.P., Dahlstrom, U., Filippatos, G., Chioncel, O., Leiro, M., Drozd, J., et al. (2013) EURObservational Research Programme: Regional Differences and 1-Year Follow-Up Results of the Heart Failure Pilot Survey (ESC-HF Pilot). European Journal of Heart Failure, 15, 808-817. https://doi.org/10.1093/eurjhf/hft050</mixed-citation></ref><ref id="scirp.123756-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Nieminen, M.S., Brutsaert, D., Dickstein, K., Drexler, H., Follath, F., Harjola, V.-P., et al. (2006) EuroHeart Failure Survey II (EHFS II): A Survey on Hospitalized Acute Heart Failure Patients: Description of Population. European Heart Journal, 27, 2725-2736. https://doi.org/10.1093/eurheartj/ehl193</mixed-citation></ref><ref id="scirp.123756-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Follath, F., Yilmaz, M.B., Delgado, J.F., Parissis, J.T., Porcher, R., Gayat, E., et al. (2011) Clinical Presentation, Management and Outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care Medicine, 37, 619-626. https://doi.org/10.1007/s00134-010-2113-0</mixed-citation></ref><ref id="scirp.123756-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Cleland, J.G., Swedberg, K., Follath, F., Komajda, M., Cohen-Solal, A., Aguilar, J.C., et al. (2003) The EuroHeart Failure Survey Programme—A Survey on the Quality of Care among Patients with Heart Failure in Europe Part 1: Patient Characteristics and Diagnosis. European Heart Journal, 24, 442-463.  
https://doi.org/10.1016/S0195-668X(02)00823-0</mixed-citation></ref><ref id="scirp.123756-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Gheorghiade, M., Abraham, W.T., Albert, N.M., Greenberg, B.H., O’Connor, C.M., She, L., et al. (2006) Systolic Blood Pressure at Admission, Clinical Characteristics, and Outcomes in Patients Hospitalized with Acute Heart Failure. JAMA, 296, 2217-2226. https://doi.org/10.1001/jama.296.18.2217</mixed-citation></ref></ref-list></back></article>